BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23419281)

  • 1. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
    Degen A; Völker B; Kapp A; Gutzmer R
    Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
    [No Abstract]   [Full Text] [Related]  

  • 2. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 3. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
    Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
    Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
    Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
    J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
    [No Abstract]   [Full Text] [Related]  

  • 5. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
    Mangold AR; Bryce A; Sekulic A
    J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term survival of a patient with metastatic melanoma treated with nivolumab and vemurafenib, with the development of vitiligo.
    Fukumoto T; Fujiwara S; Sakaguchi M; Oka M; Kiyota N; Ejima Y; Nakajima K; Nishigori C
    Eur J Dermatol; 2017 Apr; 27(2):177-178. PubMed ID: 27873735
    [No Abstract]   [Full Text] [Related]  

  • 7. Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse.
    Tauber M; Pages C; La Selva R; Schneider P; Chardin J; Osio A; Mourah S; Culine S; Vercellino L; Bagot M; Lebbé C
    Eur J Dermatol; 2013; 23(5):702-3. PubMed ID: 24135270
    [No Abstract]   [Full Text] [Related]  

  • 8. Erythema nodosum-like panniculitis in patients with melanoma treated with vemurafenib.
    Sinha R; Edmonds K; Newton-Bishop J; Gore M; Larkin J; Fearfield L
    J Clin Oncol; 2013 Jul; 31(19):e320-1. PubMed ID: 23715570
    [No Abstract]   [Full Text] [Related]  

  • 9. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 10. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 11. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
    Owen JL; Lopez IE; Desai SR
    J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of metastatic melanoma with BRAF inhibitors].
    Hafner C
    Hautarzt; 2011 Sep; 62(9):696-8. PubMed ID: 21863388
    [No Abstract]   [Full Text] [Related]  

  • 13. [Metastatic melanoma: some hope from ipilimumab and vemurafenib].
    Piérard-Franchimont C; Piérard GE
    Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BRAF mutation detection in metastatic melanoma].
    Dietel M; Enk A; Lehmann A; Bauer J; Garbe C; Kellner U; Kirchner T; Jung A; Kreipe H; Merkelbach-Bruse S; Büttner R; Rüschoff J; Schlake W; Schirmacher P; Penzel R; Stadler R
    Pathologe; 2012 Jul; 33(4):352-6. PubMed ID: 22692278
    [No Abstract]   [Full Text] [Related]  

  • 15. Fanconi syndrome induced by vemurafenib: a new renal adverse event.
    Denis D; Franck N; Fichel F; Levi C; Dupin N
    JAMA Dermatol; 2015 Apr; 151(4):453-4. PubMed ID: 25494458
    [No Abstract]   [Full Text] [Related]  

  • 16. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxic epidermal necrolysis induced by vemurafenib.
    Lapresta A; Dotor A; González-Herrada C
    Actas Dermosifiliogr; 2015 Oct; 106(8):682-3. PubMed ID: 26051238
    [No Abstract]   [Full Text] [Related]  

  • 18. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 19. RASopathic alopecia: hair changes associated with vemurafenib therapy.
    Piraccini BM; Patrizi A; Fanti PA; Starace M; Bruni F; Melotti B; Misciali C; Dika E
    J Am Acad Dermatol; 2015 Apr; 72(4):738-41. PubMed ID: 25773419
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
    Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
    Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.